Lead Investigator Discusses Pegilodecakin/PD-1 Inhibitor Combination in NSCLC

Edward B. Garon, MD, discusseds early findings with pegilodecakin in non–small cell lung cancer.

More From BioPortfolio on "Lead Investigator Discusses Pegilodecakin/PD-1 Inhibitor Combination in NSCLC"